James B Paulson, MD | |
101 W Washington St, Montezuma, IA 50171 | |
(641) 623-5690 | |
(641) 623-2229 |
Full Name | James B Paulson |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 101 W Washington St, Montezuma, Iowa |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1972586725 | NPI | - | NPPES |
2044743 | Medicaid | IA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 19701 (Iowa) | Primary |
Mailing Address | Practice Location Address |
---|---|
James B Paulson, MD Po Box 430, Montezuma, IA 50171-0430 Ph: (641) 623-5690 | James B Paulson, MD 101 W Washington St, Montezuma, IA 50171 Ph: (641) 623-5690 |
News Archive
UT Southwestern Medical Center researchers have discovered a mutation that causes a rare systemic disorder known as X-linked reticulate pigmentary disorder (XLPDR) and, significantly, the unexpected cellular mechanism by which the mutation causes the disease.
For the sixth consecutive year, the Training, Research and Education for Driving Safety (TREDS) program at the University of California, San Diego School of Medicine has been awarded a grant from the California Office of Traffic Safety to promote driving safety in older adults.
A new study shows that the vocal training of older rats reduces some of the voice problems related to their aging, such as the loss of vocal intensity that accompanies changes in the muscles of the larynx. This is an animal model of a vocal pathology that many humans face as they age.
The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).
Aileron Therapeutics, Inc. today announced the completion of the first-in-human study of its lead Stapled Peptide drug, ALRN-5281, a proprietary, long-acting growth-hormone-releasing hormone (GHRH) agonist for treating orphan endocrine disorders, including adult growth hormone (GH) deficiency and human immunodeficiency virus (HIV) lipodystrophy, as well as broader patient populations involving a wide variety of metabolic/endocrine diseases.
› Verified 3 days ago